NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A

Key Takeaways Novo Nordisk's Mim8 was well-tolerated when patients switched directly from Hemlibra treatment. Patients favored Mim8's pen-injector for ease of use, suggesting potential for strong treatment compliance. Mim8 maintained clotting activity without safety issues, with no adverse events or antibody detection.Novo Nordisk (NVO) announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating its investigational candidate, Mim8 (denecimig), as a prophyla ...